234 related articles for article (PubMed ID: 37720223)
1. Hepatic arterial infusion chemotherapy plus lenvatinib with or without programmed cell death protein-1 inhibitors for advanced cholangiocarcinoma.
Wei Z; Wang Y; Wu B; Liu Y; Wang Y; Ren Z; Yang X; Chen Q; Zhang Y
Front Immunol; 2023; 14():1235724. PubMed ID: 37720223
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of biliary stenting combined with iodine-125 seed strand followed by hepatic artery infusion chemotherapy plus lenvatinib with PD-1 inhibitor for the treatment of extrahepatic cholangiocarcinoma with malignant obstructive jaundice.
Lin LW; Ke K; Chen R; Yang WZ; Huang N; Wu ZZ
Front Immunol; 2023; 14():1286771. PubMed ID: 38288113
[TBL] [Abstract][Full Text] [Related]
3. Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors versus lenvatinib and PD-1 inhibitors for HCC refractory to TACE.
Diao L; Wang C; You R; Leng B; Yu Z; Xu Q; Cheng Y; Yin G
J Gastroenterol Hepatol; 2024 Apr; 39(4):746-753. PubMed ID: 38240156
[TBL] [Abstract][Full Text] [Related]
4. HAIC Combined with lenvatinib plus PD-1 versus lenvatinib Plus PD-1 in patients with high-risk advanced HCC: a real-world study.
Chang X; Li X; Sun P; Li Z; Sun P; Ning S
BMC Cancer; 2024 Apr; 24(1):480. PubMed ID: 38627684
[TBL] [Abstract][Full Text] [Related]
5. Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis.
Fu Y; Peng W; Zhang W; Yang Z; Hu Z; Pang Y; Hu D; Chen J; Wang J; Zhou Z; Xu L; Chen M; Zhang Y
J Gastroenterol; 2023 Apr; 58(4):413-424. PubMed ID: 36894804
[TBL] [Abstract][Full Text] [Related]
6. Postprogression treatment of lenvatinib plus PD-1 inhibitor in advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy.
An C; Fu Y; Li W; Zuo M; Wu P
Cancer; 2023 Jul; 129(14):2235-2244. PubMed ID: 37029486
[TBL] [Abstract][Full Text] [Related]
7. Clinical and biomarker analyses of hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 inhibitor for patients with advanced intrahepatic cholangiocarcinoma.
Huang Y; Du Z; Kan A; He M; Li H; Lai Z; Wen D; Huang L; Li Q; Xu L; Shi M
Front Immunol; 2024; 15():1260191. PubMed ID: 38384459
[TBL] [Abstract][Full Text] [Related]
8. Hepatic arterial infusion chemotherapy, lenvatinib plus programmed cell death protein-1 inhibitors: A promising treatment approach for high-burden hepatocellular carcinoma.
Fu S; Xu Y; Mao Y; He M; Chen Z; Huang S; Li D; Lv Y; Wu J
Cancer Med; 2024 May; 13(9):e7105. PubMed ID: 38686567
[TBL] [Abstract][Full Text] [Related]
9. Lenvatinib Plus Programmed Cell Death Protein-1 Inhibitor Beyond First-Line Systemic Therapy in Refractory Advanced Biliary Tract Cancer: A Real-World Retrospective Study in China.
Shi C; Li Y; Yang C; Qiao L; Tang L; Zheng Y; Chen X; Qian Y; Yang J; Wu D; Xie F
Front Immunol; 2022; 13():946861. PubMed ID: 35967452
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study.
Zhu C; Li H; Yang X; Wang S; Wang Y; Zhang N; Wang Y; Xue J; Zhang L; Ning C; Yang X; Xun Z; Chao J; Long J; Sang X; Zhu Z; Zhao H
Cancer Immunol Immunother; 2023 Sep; 72(9):2949-2960. PubMed ID: 37247023
[TBL] [Abstract][Full Text] [Related]
11. Patients with hepatocellular carcinoma extrahepatic metastases can benefit from hepatic arterial infusion chemotherapy combined with lenvatinib plus programmed Death-1 inhibitors.
Guan R; Zhang N; Deng M; Lin Y; Huang G; Fu Y; Zheng Z; Wei W; Zhong C; Zhao H; Mei J; Guo R
Int J Surg; 2024 Mar; ():. PubMed ID: 38549220
[TBL] [Abstract][Full Text] [Related]
12. Lenvatinib combined with PD-1 inhibitor plus Gemox chemotherapy versus plus HAIC for advanced biliary tract cancer.
Zhang T; Zhu C; Zhang N; Zhang L; Wang S; Xun Z; Xu Y; Yang X; Lu X; Zhao H
Int Immunopharmacol; 2024 Mar; 129():111642. PubMed ID: 38325044
[TBL] [Abstract][Full Text] [Related]
13. Hepatic arterial infusion chemotherapy with or without lenvatinib for unresectable cholangiocarcinoma: a single-center retrospective study.
Wang Y; Wei Z; Zhang Z; Xu J; Wang Y; Chen Q; Zhang Y
Hepat Oncol; 2023 Jun; 10(2):HEP49. PubMed ID: 37850031
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of lenvatinib plus durvalumab combined with hepatic arterial infusion chemotherapy for unresectable intrahepatic cholangiocarcinoma.
Zhao R; Zhou J; Miao Z; Xiong X; Wei W; Li S; Guo R
Front Immunol; 2024; 15():1397827. PubMed ID: 38799453
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors for advanced hepatocellular carcinoma with macrovascular invasion.
Zhang Y; Zhang H; Xu H; Wang Y; Feng L; Yi F
World J Surg Oncol; 2024 May; 22(1):122. PubMed ID: 38711095
[TBL] [Abstract][Full Text] [Related]
16. Transarterial chemoembolization plus lenvatinib with or without a PD-1 inhibitor for advanced and metastatic intrahepatic cholangiocarcinoma: a retrospective real-world study.
Ning Z; Xie L; Yan X; Hua Y; Shi W; Lin J; Xu L; Meng Z
Br J Radiol; 2023 Oct; 96(1150):20230079. PubMed ID: 37660471
[TBL] [Abstract][Full Text] [Related]
17. Correlation and efficacy of TACE combined with lenvatinib plus PD-1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features.
Zou X; Xu Q; You R; Yin G
Cancer Med; 2023 May; 12(10):11315-11333. PubMed ID: 36951443
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study.
Chen S; Xu B; Wu Z; Wang P; Yu W; Liu Z; Huang X; Wu Y; Li T; Guo W
BMC Cancer; 2021 Oct; 21(1):1126. PubMed ID: 34670506
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes of hepatic arterial infusion chemotherapy combined with tyrosine kinase inhibitors and anti-PD-1 immunotherapy for unresectable intrahepatic cholangiocarcinoma.
Zhang N; Yu BR; Wang YX; Zhao YM; Zhou JM; Wang M; Wang LR; Lin ZH; Zhang T; Wang L
J Dig Dis; 2022 Aug; 23(8-9):535-545. PubMed ID: 36148493
[TBL] [Abstract][Full Text] [Related]
20. The treatment of transarterial chemoembolization/hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitor is effective against hepatocellular carcinoma with portal vein tumor thrombus: A systematic review.
Yuanren G; Yin L; Liu R; Cui Y
Front Oncol; 2023; 13():1054072. PubMed ID: 36969065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]